Low Dose Aprepitant for Patients Receiving Carboplatin

Model scores of the 29,894 trials active now.

Model score 26% for any early termination, 10% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 16% of the time (1,198 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2021-02-11. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: chemotherapycarboplatinpatientsreceivingnausea and
  Phrases that lowered it: participantssingledexamethasoneefficacyoral
• Sponsor's past termination rate: 16.7% (raises risk) · Sponsor's track record
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Has a data monitoring committee: Yes (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Disease area, cancer: No (lowers risk) · Disease area
• Design: single group (raises risk) · Design
• Drug's FAERS reports with a death: 17.5% (lowers risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports before start: 209258 (lowers risk) · Drug's FDA history
• Primary purpose: treatment (raises risk) · Design
• Blinding: none (raises risk) · Design
• Drug's FAERS reports in the prior 12 months: 45604 (lowers risk) · Drug's FDA history
• Number of arms: 1 (raises risk) · Design
• Trials the sponsor started in the prior 2 years: 18 (lowers risk) · Sponsor's track record
• Collaborators: 1 (raises risk) · Design
• Drugs with FDA adverse-event history: 4 (lowers risk) · Drug's FDA history
• Maximum age: not given (raises risk) · Who can join
• Drug's FAERS reports marked serious: 83.9% (lowers risk) · Drug's FDA history

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• An Efficacy and Safety Study of Oral and Intravenous Palonosetron for the Prevention of Nausea and Vomiting NCT01363479 · started 2011 · scored riskier than 65% of active trials completed
• Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients NCT06007586 · started 2024 · scored riskier than 23% of active trials completed
• Aprepitant Without Steroid in Preventing Chemotherapy-induced Nausea and Vomiting in Patients With Colorectal Cancer NCT02909478 · started 2017 · scored riskier than 27% of active trials completed
• Safety and Efficacy of Aprepitant, Ramosetron, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Patients With Ovarian Cancer Treated With Taxane/Carboplatin NCT01012336 · started 2010 · scored riskier than 26% of active trials completed
• Aprepitant ,Olanzapine,Palonosetron and Dexamethasone for the Prevention of Chemotherapy-induced Nausea and Vomiting NCT02484911 · started 2015 · scored riskier than 48% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.